Predictive biomarkers of immunotherapy response are critical for clinical practice. In this study, baseline plasma sCD27 was ...
The FDA review – which is due to be completed by 28th September – revolves around the results of the HERCULES trial which ...
This Phase 2 trial aims to assess the safety, tolerability, and foralumab’s effect on microglial activation in patients with na-SPMS. Intranasal foralumab offers a novel approach to potentially ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback